Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CBP501 + Cisplatin |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CBP501 | CBP-501|CBP 501 | CHK1 Inhibitor 18 | CBP501 is a peptide drug that inhibits the activity of several kinases responsible for phosphorylation of CDC25C, including MAPKAP-K2, C-Tak1, and CHK1, resulting in disruption of the G2 checkpoint and potentially leading to cell-cycle arrest and increased tumor cell death (PMID: 17237275, PMID: 29088764). | |
Cisplatin | Platinol | CDDP | Chemotherapy - Platinum 7 | Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04953962 | Phase II | CBP501 + Cisplatin + Nivolumab Cisplatin + Nivolumab CBP501 + Cisplatin | Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer | Completed | USA | 0 |